keyword
MENU ▼
Read by QxMD icon Read
search

Inform study relapsed cancer

keyword
https://www.readbyqxmd.com/read/28917257/exploiting-molecular-genomics-in-precision-radiation-oncology-a-marriage-of-biological-and-physical-precision
#1
Janice S H Tan, Xiaotian Lin, Kevin L M Chua, Paula Y Lam, Khee-Chee Soo, Melvin L K Chua
Achieving local tumour control is paramount for cure in head and neck and prostate cancers. With the transition to precision radiotherapy (RT) techniques, survival rates have improved in the majority of these cancers, but a substantial proportion of 30-40% still relapse following primary treatment. Recent large-scale molecular profiling studies have revealed unique biological events that could explain for tumour aggression and resistance to therapies, redefining the molecular taxonomy of head and neck and prostate cancers...
September 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28906402/barriers-and-facilitators-to-participation-in-clinical-trial-among-lymphoma-patients-from-sun-yat-sen-university-cancer-center-in-china-an-observation-study
#2
Qiuhuan Kong, Hua Mei, Yuerong Lai, Simei Shi, Yaner Li, Lianzhu He, Hui-Ying Qin
Recruitment rate of clinical trials in cancer patients is pretty low in China. Little is known about factors influencing trial recruitment in Chinese cancer patients. The aim of present study is to evaluate the barriers and facilitators to participation in clinical trials among lymphoma patients in China.From December 2014 to August 2015, the survey was carried out in the Department of Medical Oncology in Sun Yat-sen University Cancer Center. A self-made questionnaire was used among lymphoma patients (N = 331) to evaluate their attitude toward clinical trials...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28855612/functional-proteomics-outlines-the-complexity-of-breast-cancer-molecular-subtypes
#3
Angelo Gámez-Pozo, Lucía Trilla-Fuertes, Julia Berges-Soria, Nathalie Selevsek, Rocío López-Vacas, Mariana Díaz-Almirón, Paolo Nanni, Jorge M Arevalillo, Hilario Navarro, Jonas Grossmann, Francisco Gayá Moreno, Rubén Gómez Rioja, Guillermo Prado-Vázquez, Andrea Zapater-Moros, Paloma Main, Jaime Feliú, Purificación Martínez Del Prado, Pilar Zamora, Eva Ciruelos, Enrique Espinosa, Juan Ángel Fresno Vara
Breast cancer is a heterogeneous disease comprising a variety of entities with various genetic backgrounds. Estrogen receptor-positive, human epidermal growth factor receptor 2-negative tumors typically have a favorable outcome; however, some patients eventually relapse, which suggests some heterogeneity within this category. In the present study, we used proteomics and miRNA profiling techniques to characterize a set of 102 either estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+) or triple-negative formalin-fixed, paraffin-embedded breast tumors...
August 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28819411/comprehensive-study-of-prognostic-risk-factors-of-patients-underwent-pneumonectomy
#4
Chang Gu, Rui Wang, Xufeng Pan, Qingyuan Huang, Jizhuang Luo, Jiajie Zheng, Yiyang Wang, Jianxin Shi, Haiquan Chen
Introduction: To investigate postoperative complications and the prognostic risk factors of patients underwent pneumonectomy. Methods: Four hundred and six patients underwent pneumonectomy were subjected to the study. All the clinicopathologic data including age, gender, smoking history, surgical treatment, postoperative complications, tumor staging and the follow-up information were investigated. Results: The 30-day and 90-day mortality rates were 3.2% and 6.2%, respectively. Postoperative complications developed in 149 patients (36...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28753810/validation-of-cyclic-adenosine-monophosphate-phosphodiesterase-4d7-for-its-independent-contribution-to-risk-stratification-in-a-prostate-cancer-patient-cohort-with-longitudinal-biological-outcomes
#5
Marcia Alves de Inda, Dianne van Strijp, Eveline den Biezen-Timmermans, Anne van Brussel, Janneke Wrobel, Hans van Zon, Pieter Vos, George S Baillie, Pierre Tennstedt, Thorsten Schlomm, Miles D Houslay, Chris Bangma, Ralf Hoffmann
BACKGROUND: The clinical metrics used to date to assess the progression risk of newly diagnosed prostate cancer patients only partly represent the true biological aggressiveness of the underlying disease. OBJECTIVE: Validation of the prognostic biomarker phosphodiesterase-4D7 (PDE4D7) in predicting longitudinal biological outcomes in a historical surgery cohort to improve postsurgical risk stratification. DESIGN, PATIENTS, AND METHODS: RNA was extracted from biopsy punches of resected tumors from 550 patients...
June 13, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753801/age-%C3%A2-40-years-is-associated-with-adverse-outcome-in-metastatic-germ-cell-cancer-despite-appropriate-intended-chemotherapy
#6
Rowan E Miller, Sarah C Markt, Elizabeth O'Donnell, Brandon Bernard, Laurence K Albiges, Clair Beard, Christopher J Sweeney
BACKGROUND: Age ≥40 yr is associated with poorer testicular cancer outcomes in population-based studies. OBJECTIVE: To assess the association between age (≥40 yr) and outcomes among men with germ cell tumors (GCTs) in a large hospital registry. DESIGN, SETTING, AND PARTICIPANTS: Electronic medical records for 1095 GCT patients treated at Dana-Farber Cancer Institute between 1997 and 2013 were reviewed. Information regarding histology, stage, treatment, and patient characteristics was obtained...
October 26, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28680951/health-related-quality-of-life-of-patients-with-acute-myeloid-leukemia-a-systematic-literature-review
#7
REVIEW
Ellen E Korol, Sisi Wang, Karissa Johnston, Farhad Ravandi-Kashani, Mark Levis, Floortje van Nooten
INTRODUCTION: Patients with acute myeloid leukemia (AML), especially those with relapsed or refractory AML, have poor clinical prognosis and outcomes. Health-related quality of life (HRQoL) assessments have become increasingly important in oncology, aiding in identifying and informing supportive therapy needs during treatment and beyond; however, HRQoL in hematology, and AML in particular, has received relatively minor attention. The aim was to identify and summarize estimates of HRQoL in patients with AML, including patients with relapsed or refractory AML...
2017: Oncology and Therapy
https://www.readbyqxmd.com/read/28670174/systematic-review-on-the-accuracy-of-positron-emission-tomography-computed-tomography-and-positron-emission-tomography-magnetic-resonance-imaging-in-the-management-of-ovarian-cancer-is-functional-information-really-needed
#8
REVIEW
Subapriya Suppiah, Wing Liong Chang, Hasyma Abu Hassan, Chalermrat Kaewput, Andi Anggeriana Andi Asri, Fathinul Fikri Ahmad Saad, Abdul Jalil Nordin, Sobhan Vinjamuri
Ovarian cancer (OC) often presents at an advanced stage with frequent relapses despite optimal treatment; thus, accurate staging and restaging are required for improving treatment outcomes and prognostication. Conventionally, staging of OC is performed using contrast-enhanced computed tomography (CT). Nevertheless, recent advances in the field of hybrid imaging have made positron emission tomography/CT (PET/CT) and PET/magnetic resonance imaging (PET/MRI) as emerging potential noninvasive imaging tools for improved management of OC...
July 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28641315/sequential-vs-concurrent-epirubicin-and-docetaxel-as-adjuvant-chemotherapy-for-high-risk-node-negative-early-breast-cancer-an-interim-analysis-of-a-randomised-phase-iii-study-from-the-hellenic-oncology-research-group
#9
RANDOMIZED CONTROLLED TRIAL
Dimitrios Mavroudis, Emmanouil Saloustros, Ioannis Boukovinas, Pavlos Papakotoulas, Stylianos Kakolyris, Nikolaos Ziras, Charalampos Christophylakis, Nikolaos Kentepozidis, Georgios Fountzilas, Georgios Rigas, Ioannis Varthalitis, Konstantinos Kalbakis, Sofia Agelaki, Dora Hatzidaki, Vasilios Georgoulias
BACKGROUND: Sequential anthracyclines and taxanes are standard adjuvant chemotherapy for patients with high-risk axillary node-positive breast cancer. We compared a sequential to a concurrent regimen in high-risk node-negative early breast cancer. METHODS: Patients were eligible if they had tumours >2 cm or T1c with two of the following characteristics: no oestrogen receptor (ER) and progesterone receptor (PR) expression, histological grade III, Ki67 >40% and vascular, lymphovascular or perineural invasion...
July 11, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28600478/clinical-implications-of-monitoring-circulating-tumor-dna-in-patients-with-colorectal-cancer
#10
Lone V Schøler, Thomas Reinert, Mai-Britt W Ørntoft, Christine G Kassentoft, Sigrid S Árnadóttir, Søren Vang, Iver Nordentoft, Michael Knudsen, Philippe Lamy, Ditte Andreasen, Frank V Mortensen, Anders R Knudsen, Katrine Stribolt, Kim Sivesgaard, Peter Mouritzen, Hans J Nielsen, Søren Laurberg, Torben F Ørntoft, Claus L Andersen
Purpose: We investigated whether detection of ctDNA after resection of colorectal cancer identifies the patients with the highest risk of relapse and, furthermore, whether longitudinal ctDNA analysis allows early detection of relapse and informs about response to intervention.Experimental Design: In this longitudinal cohort study, we used massively parallel sequencing to identify somatic mutations and used these as ctDNA markers to detect minimal residual disease and to monitor changes in tumor burden during a 3-year follow-up period...
June 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28588019/enasidenib-induces-acute-myeloid-leukemia-cell-differentiation-to-promote-clinical-response
#11
Michael D Amatangelo, Lynn Quek, Alan Shih, Eytan M Stein, Mikhail Roshal, Muriel D David, Benoit Marteyn, Noushin Rahnamay Farnoud, Stephane de Botton, Olivier A Bernard, Bin Wu, Katharine E Yen, Martin S Tallman, Elli Papaemmanuil, Virginie Penard-Lacronique, Anjan Thakurta, Paresh Vyas, Ross L Levine
Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation block. Single-agent enasidenib (AG-221/CC-90007), a selective mutant IDH2 (mIDH2) inhibitor, produced an overall response rate of 40.3% in relapsed/refractory AML (rrAML) patients with mIDH2 in a phase 1 trial. However, its mechanism of action and biomarkers associated with response remain unclear...
August 10, 2017: Blood
https://www.readbyqxmd.com/read/28578690/evaluation-of-treatment-response-and-resistance-in-metastatic-renal-cell-cancer-mrcc-using-integrated-18-f-fluorodeoxyglucose-18-f-fdg-positron-emission-tomography-magnetic-resonance-imaging-pet-mri-the-remap-study
#12
Christian Kelly-Morland, Sarah Rudman, Paul Nathan, Susan Mallett, Giovanni Montana, Gary Cook, Vicky Goh
BACKGROUND: Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as standard size-related response criteria do not necessarily accurately reflect clinical benefit, as they may be less pronounced or occur later in therapy than devascularisation. The challenge for imaging is providing timely assessment of disease status allowing therapies to be tailored to ensure ongoing clinical benefit...
June 2, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28523039/borderline-tumors-of-the-ovary-a-clinicopathological-study
#13
Samia Yasmeen, Abdul Hannan, Fareeha Sheikh, Amir Ali Syed, Neelam Siddiqui
OBJECTIVE: To report experience with borderline ovarian tumors (BOTs) in a developing country like Pakistan with limited resources and weak database of health system. METHODS: Patients with BOTs managed at Shaukat Khanum Cancer hospital, Lahore, Pakistan from 2004 to 2014 were included and reviewed retrospectively. Data was recorded on histopathological types, age, CA-125, stage of disease, treatment modalities and outcomes. RESULTS: Eighty-six patients with BOT were included with a median age of 35 years...
March 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/28493031/foxc1-overexpression-is-a-marker-of-poor-response-to-anthracycline-based-adjuvant-chemotherapy-in-sporadic-triple-negative-breast-cancer
#14
Y L Xu, R Yao, J Li, Y D Zhou, F Mao, B Pan, Q Sun
PURPOSE: Because of its aggressive characteristics and poor prognosis, triple-negative breast cancer (TNBC) has become a hot topic in cancer research. Chemotherapy is currently the only treatment for patients with TNBC. The transcription factor FOXC1 has been associated with TNBC prognosis, but little is known about its effect on chemosensitivity. The aim of this study was to investigate the effects of FOXC1 on chemosensitivity. METHODS: A case-control study was performed on 25 TNBC patients who experienced relapse and/or metastasis...
June 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28486040/gata2-expression-and-biochemical-recurrence-following-salvage-radiation-therapy-for-relapsing-prostate-cancer
#15
Jessica L Robinson, Katherine S Tzou, Alexander S Parker, Michael G Heckman, Kevin J Wu, Tracy W Hilton, Thomas M Pisansky, Steven E Schild, Jennifer L Peterson, Laura A Vallow, Steven J Buskirk
OBJECTIVE: High GATA2 expression has been associated with an increased risk of poor clinical outcomes after radical prostatectomy; however, this has not been studied in relation to risk of biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer after radical prostatectomy. Our aim was to evaluate the association between protein expression levels of GATA2 in primary prostate cancer tumour samples and the risk of BCR after SRT. METHODS: 109 males who were treated with SRT were included...
July 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28469967/elevated-ascl2-expression-in-breast-cancer-is-associated-with-the-poor-prognosis-of-patients
#16
Hui Xu, Xi-Long Zhao, Xue Liu, Xu-Gang Hu, Wen-Juan Fu, Qian Li, Yan Wang, Yi-Fang Ping, Xia Zhang, Xiu-Wu Bian, Xiao-Hong Yao
Achaete scute-like 2 (ASCL2) is a member of the basic helix-loop-helix (bHLH) transcription factors, and is expressed mainly in intestinal stem cells under normal conditions. Recently, aberrantly elevated ASCL2 was detected in cancer tissues, but the clinical relevance of ASCL2 in breast cancers remains to be decided. In this study, we evaluated the expression of ASCL2 and its relationship to cancer progression in specimens from 191 cases of breast cancer patients with follow-up information. The results indicated that ASCL2 was highly expressed in cancer cells while it was undetectable in normal epithelial cells...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28458816/orthotopic-neobladder-in-patient-with-locally-advanced-small-cell-carcinoma-of-the-bladder-a-case-report-and-review-of-the-literature
#17
Pero Bokarica
Small cell carcinoma of the urinary bladder (SCCUB) is a rare, aggressive variant of neuroendocrine nonepithelial tumor. The best treatment results are achieved by combined cystectomy and chemotherapy. Same as in urothelial bladder cancer, a question remains about the urinary diversion in locally advanced disease. Studies on surgical treatment of patients with SCCUB most often do not clearly specify the type of urinary diversion performed, and we could not find information that orthotopic urinary diversion was performed in those patients...
February 2017: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/28424419/integrated-analysis-of-genes-associated-with-poor-prognosis-of-patients-with-colorectal-cancer-liver-metastasis
#18
Zhenyuan Qian, Guobing Zhang, Guangyuan Song, Ji Shi, Lijie Gong, Yiping Mou, Yong Han
Colorectal cancer (CRC) is one of the most common malignances in the gut. Liver is the most common metastasis site of CRC. This study focuses on the primary CRC and its liver metastasis, aiming to discover several liver metastasis related genes and provide therapeutic candidates. We compared gene expression patterns among the groups of normal colorectal mucosa, primary tumor and the liver metastasis using a CRC gene expression dataset. 84 genes were found to be upregulated in both primary tumor and liver metastases...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28416639/absent-progesterone-receptor-expression-in-the-lymph-node-metastases-of-er-positive-her2-negative-breast-cancer-is-associated-with-relapse-on-tamoxifen
#19
Cameron E Snell, Madeline Gough, Kathryn Middleton, Michael Hsieh, Lauren Furnas, Brenton Seidl, Kristen Gibbons, Christopher Pyke, Catherine Shannon, Natasha Woodward, Jane E Armes
AIMS: Progesterone receptor (PR) expression is prognostic in early stage breast cancer. There are several reports of discordant expression between primary tumour and axillary lymph node (ALN) metastasis expression of oestrogen receptor (ER) and PR. We sought to determine whether expression of these biomarkers in the synchronous ALN metastases of ER positive (+), HER2 negative (-) breast cancer could provide more accurate prognostic information. METHODS: The retrospective cohort included 229 patients from a single institution with ER+, HER2- breast cancer who had synchronous ALN metastatic disease (2005-2014)...
April 17, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28407030/intratumoral-heterogeneity-pathways-to-treatment-resistance-and-relapse-in-human-glioblastoma
#20
M A Qazi, P Vora, C Venugopal, S S Sidhu, J Moffat, C Swanton, S K Singh
Intratumoral heterogeneity (ITH) has increasingly being described for multiple cancers as the root cause of therapy resistance. Recent studies have started to explore the scope of ITH in glioblastoma (GBM), a highly aggressive and fatal form of brain tumor, to explain its inevitable therapy resistance and disease relapse. In this review, we detail the emerging data that explores the extensive genetic, cellular and functional ITH present in GBM. We discuss current experimental models of human GBM recurrence and suggest harnessing new technologies (CRISPR-Cas9 screening, CyTOF, cellular barcoding, single cell analysis) to delineate GBM ITH and identify treatment-refractory cell populations, thus opening new therapeutic windows...
July 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
120954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"